Skin sensitisation is one of the success stories in the effective transition from in vivo testing to an integrated in vitro testing approach. Mechanistically, the process underlying skin sensitization has been well characterized within an Adverse Outcome Pathway (AOP). This has led to a number of in vitro assays being developed to cover the Key Events within the AOP – these include the Direct Peptide Reactivity Assay (DPRA), KeratinoSens™ and the human Cell Line Activation Test (h-CLAT).
This month, Cyprotex announced the launch of its h-CLAT service, alongside its existing KeratinoSens™ and DPRA services. We are now one of the few companies which offer all three of the in vitro assays for supporting skin sensitization classification.
We have also co-published our research in the field of MEA and human iPSC-derived cardiomyocytes in the Toxicological Sciences journal, and co-presented a poster with Sciex on our combined analytical capabilities at the DMDG meeting.
Learn more about our new capabilities and research below.